Results 141 to 150 of about 57,115 (246)

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source

Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy

, 2017
Zhuanglei Gao,1 Zhaoxia Li,2 Jieke Yan,3 Peilin Wang1 1Department of General Surgery, 2Department of Pediatrics, 3Department of Renal Transplantation, The Second Hospital of Shandong University, Jinan, Shandong, People’s Republic of China ...
Li Z, Yan J, Wang P, Gao Z
core  

Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Neuroendocrine neoplasms, which occur throughout the human body, as well as adrenocortical carcinoma and pheochromocytoma, which originate in the adrenal gland, are primarily classified as rare malignancies. Immunotherapy, including immune checkpoint inhibitors (ICIs), is generally not incorporated into the standard care protocols for these ...
Akihiro Ohmoto, Shunji Takahashi, Shigehisa Kitano   +2 more
wiley   +1 more source

A POLE P286R‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer with histological and morphological properties of hepatocellular carcinoma, characterized by an aggressive course of the disease and unfavorable prognosis. Given the rarity of the pathology and the lack of unambiguous therapeutic protocols, descriptions of ...
Aleksey Chernev, Alina Kaurtseva, Ruslan Abasov, Rafael Enikeev, Nina Gegelia, Gulnara Abdrakova, Natalia Usman, Alexander Druy, Grigory Raskin   +8 more
wiley   +1 more source

Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR‐Negative Ovarian Cancer Cells

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Progesterone induces rapid cellular responses in progesterone receptor (PR)‐negative ovarian cancer cells that are consistent with non‐genomic progesterone signaling. Vasohibin‐2 (VASH2), originally identified as a pro‐angiogenic factor, has recently been recognized as a tubulin carboxypeptidase involved in microtubule regulation ...
Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Kohei Tamura, Eri Suizu, Kazuki Yamamoto, Akiyo Taneichi, Yuji Takei, Hiroaki Mizukami, Hiroyuki Fujiwara   +9 more
wiley   +1 more source

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Although older adults (≥ 75 years) constitute a large proportion of patients with unresectable pancreatic cancer (PC), they remain underrepresented in clinical trials. Biweekly gemcitabine plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains ...
Kenji Ikezawa, Toshihiro Imai, Ryoji Takada, Takuo Yamai, Nobuyasu Fukutake, Makiko Urabe, Yugo Kai, Kaori Mukai, Tasuku Nakabori, Kazuyoshi Ohkawa   +9 more
wiley   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, Volume 159, Issue 5, Page 1322-1336, 1 September 2026.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

Targeting FAR1 to inhibit intestinal macrophage ferroptosis: repurposing irinotecan as a novel sepsis therapy. [PDF]

Apoptosis
Deng H, Wang W, Li Q, Xiang X, Zhu Y, Zhang Z, Zhou X, Wu Y, Zhang J, Liu L, Li T.   +10 more
europepmc   +1 more source